{"id":325308,"date":"2026-10-23T14:17:00","date_gmt":"2026-10-23T08:47:00","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=325308"},"modified":"2026-10-23T14:17:00","modified_gmt":"2026-10-23T08:47:00","slug":"finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/","title":{"rendered":"3 Finished Dosage Generics, Anti-Retroviral and Active Ingredient Leader and Complex Oncology Generics Stocks With a Strong Future Roadmap: Strides Pharma Science, Laurus Labs and Natco Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Strides Pharma Science, Laurus Labs and Natco Pharma: ROE of 15.4% to 17.9% and FY22 to FY26 revenue CAGR of 8.5% to 21.0%. Prices as of 22 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three US generics and complex oncology drug stocks to watch are Strides Pharma Science, Laurus Labs and Natco Pharma. Their return on equity ranges from 15.4% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 21.0%. Strides Pharma Science has the highest return on equity at 17.9%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>US generics and complex oncology drug stocks let investors follow pharmaceutical companies that sell finished medicines in regulated markets. Strides Pharma Science, Laurus Labs and Natco Pharma cover finished dosage generics, an anti-retroviral and active ingredient leader and a maker of complex oncology generics.<\/p>\n<p>This list covers three US generics and complex oncology drug stocks with complete current figures: Strides Pharma Science, Laurus Labs and Natco Pharma. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#What_Are_US_Generics_and_Complex_Oncology_Drug_Stocks\" title=\"What Are US Generics and Complex Oncology Drug Stocks?\">What Are US Generics and Complex Oncology Drug Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#US_Generics_and_Complex_Oncology_Drug_Stocks_at_a_Glance\" title=\"US Generics and Complex Oncology Drug Stocks at a Glance\">US Generics and Complex Oncology Drug Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Why_Do_US_Generics_and_Complex_Oncology_Drug_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do US Generics and Complex Oncology Drug Stocks Have a Strong Roadmap in India?\">Why Do US Generics and Complex Oncology Drug Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Why_Strides_Pharma_Science_Features_Among_These_US_Generics_and_Complex_Oncology_Drug_Stocks\" title=\"Why Strides Pharma Science Features Among These US Generics and Complex Oncology Drug Stocks\">Why Strides Pharma Science Features Among These US Generics and Complex Oncology Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Why_Laurus_Labs_Features_Among_These_US_Generics_and_Complex_Oncology_Drug_Stocks\" title=\"Why Laurus Labs Features Among These US Generics and Complex Oncology Drug Stocks\">Why Laurus Labs Features Among These US Generics and Complex Oncology Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Why_Natco_Pharma_Features_Among_These_US_Generics_and_Complex_Oncology_Drug_Stocks\" title=\"Why Natco Pharma Features Among These US Generics and Complex Oncology Drug Stocks\">Why Natco Pharma Features Among These US Generics and Complex Oncology Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Strides_Pharma_Science_vs_Laurus_Labs_vs_Natco_Pharma_on_Key_Financials\" title=\"Strides Pharma Science vs Laurus Labs vs Natco Pharma on Key Financials\">Strides Pharma Science vs Laurus Labs vs Natco Pharma on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Key_Risks_to_Check_Before_Investing_in_US_Generics_and_Complex_Oncology_Drug_Stocks\" title=\"Key Risks to Check Before Investing in US Generics and Complex Oncology Drug Stocks\">Key Risks to Check Before Investing in US Generics and Complex Oncology Drug Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Final_Thoughts_on_US_Generics_and_Complex_Oncology_Drug_Stocks\" title=\"Final Thoughts on US Generics and Complex Oncology Drug Stocks\">Final Thoughts on US Generics and Complex Oncology Drug Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#What_are_US_generics_and_complex_oncology_drug_stocks\" title=\"What are US generics and complex oncology drug stocks?\">What are US generics and complex oncology drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Which_US_generics_and_complex_oncology_drug_stocks_are_covered_in_this_list\" title=\"Which US generics and complex oncology drug stocks are covered in this list?\">Which US generics and complex oncology drug stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Why_do_US_generics_and_complex_oncology_drug_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do US generics and complex oncology drug stocks have a strong future roadmap in India?\">Why do US generics and complex oncology drug stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#How_has_Strides_Pharma_Science_performed_financially\" title=\"How has Strides Pharma Science performed financially?\">How has Strides Pharma Science performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#How_has_Laurus_Labs_performed_financially\" title=\"How has Laurus Labs performed financially?\">How has Laurus Labs performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#How_has_Natco_Pharma_performed_financially\" title=\"How has Natco Pharma performed financially?\">How has Natco Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#What_risks_should_investors_check_before_buying_US_generics_and_complex_oncology_drug_stocks\" title=\"What risks should investors check before buying US generics and complex oncology drug stocks?\">What risks should investors check before buying US generics and complex oncology drug stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and-complex-oncology-generics-stocks-roadmap-overture-list\/#Is_this_list_of_US_generics_and_complex_oncology_drug_stocks_investment_advice\" title=\"Is this list of US generics and complex oncology drug stocks investment advice?\">Is this list of US generics and complex oncology drug stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_US_Generics_and_Complex_Oncology_Drug_Stocks\"><\/span><strong>What Are US Generics and Complex Oncology Drug Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>US generics and complex oncology drug stocks are listed pharmaceutical companies that make generic formulations and active ingredients for regulated markets. Their earnings depend on approvals, launches and plant compliance.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"US_Generics_and_Complex_Oncology_Drug_Stocks_at_a_Glance\"><\/span><strong>US Generics and Complex Oncology Drug Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/star\/strides-pharma-science-ltd-share-price-today\">Strides Pharma Science<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,025.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,491<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.57<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/lauruslabs\/laurus-labs-ltd-share-price-today\">Laurus Labs<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,012.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">111,434<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">102.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.48<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">785.15<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Strides Pharma Science and Natco Pharma trade at a P\/E below the industry P\/E, while Laurus Labs trades above it, which reflects the growth the market already expects. Readers comparing US generics and complex oncology drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_US_Generics_and_Complex_Oncology_Drug_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do US Generics and Complex Oncology Drug Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>US generics and complex oncology drug stocks have a strong roadmap in India because global buyers keep turning to Indian makers for affordable medicines, and complex products earn better margins.<\/p>\n<ul>\n<li><strong>Complex launches.<\/strong> Difficult-to-make generics face fewer competitors.<\/li>\n<li><strong>Backward integration.<\/strong> Own ingredient supply supports cost and reliability.<\/li>\n<li><strong>Regulated markets.<\/strong> Sales in the United States and Europe diversify earnings.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Strides_Pharma_Science_Features_Among_These_US_Generics_and_Complex_Oncology_Drug_Stocks\"><\/span><strong>Why Strides Pharma Science Features Among These US Generics and Complex Oncology Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the US generics and complex oncology drug stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.<\/p>\n<p>The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<p><strong>What to watch:<\/strong> Track new US launches and the pace of price erosion in generic categories.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Laurus_Labs_Features_Among_These_US_Generics_and_Complex_Oncology_Drug_Stocks\"><\/span><strong>Why Laurus Labs Features Among These US Generics and Complex Oncology Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the regulated market pharma shares on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.<\/p>\n<p>Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%.<\/p>\n<p>In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P\/E of 102.2, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.<\/p>\n<p><strong>What to watch:<\/strong> Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Natco_Pharma_Features_Among_These_US_Generics_and_Complex_Oncology_Drug_Stocks\"><\/span><strong>Why Natco Pharma Features Among These US Generics and Complex Oncology Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.<\/p>\n<p>Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.<\/p>\n<p>The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the timing of key product launches in the US and the contribution from new drug approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Strides_Pharma_Science_vs_Laurus_Labs_vs_Natco_Pharma_on_Key_Financials\"><\/span><strong>Strides Pharma Science vs Laurus Labs vs Natco Pharma on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three US generics and complex oncology drug stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Strides Pharma Science<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,202<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,009<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">575<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Laurus Labs<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,951<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,868<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">890<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Natco Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,376<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,372<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">31.4%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Strides Pharma Science posts the highest return on equity in this group at 17.9%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with US generics and complex oncology drug stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_US_Generics_and_Complex_Oncology_Drug_Stocks\"><\/span><strong>Key Risks to Check Before Investing in US Generics and Complex Oncology Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these US generics and complex oncology drug stocks, the main points are: Long-term regulated market pharma shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Pricing in export markets.<\/strong> Competition can weigh on generic prices.<\/li>\n<li><strong>Regulatory checks.<\/strong> Plant inspections can delay launches.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter US generics and complex oncology drug stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_US_Generics_and_Complex_Oncology_Drug_Stocks\"><\/span><strong>Final Thoughts on US Generics and Complex Oncology Drug Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>US generics and complex oncology drug stocks reward investors who follow approvals, launches and plant compliance together. Strides Pharma Science, Laurus Labs and Natco Pharma each have a clear pipeline. Based on the 22 October 2026 close, Strides Pharma Science trades at Rs 1,025.3, Laurus Labs at Rs 2,012.5 and Natco Pharma at Rs 785.15.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track US generics and complex oncology drug stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_US_generics_and_complex_oncology_drug_stocks\"><\/span><strong>What are US generics and complex oncology drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> US generics and complex oncology drug stocks are listed pharmaceutical companies that make generic formulations and active ingredients for regulated markets. Their earnings depend on approvals, launches and plant compliance. This list looks at three of them, Strides Pharma Science, Laurus Labs and Natco Pharma, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_US_generics_and_complex_oncology_drug_stocks_are_covered_in_this_list\"><\/span><strong>Which US generics and complex oncology drug stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Strides Pharma Science, Laurus Labs and Natco Pharma. Based on the 22 October 2026 close, Strides Pharma Science traded at Rs 1,025.3, Laurus Labs at Rs 2,012.5 and Natco Pharma at Rs 785.15. Their return on equity ranges from 15.4% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 21.0%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_US_generics_and_complex_oncology_drug_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do US generics and complex oncology drug stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> US generics and complex oncology drug stocks have a strong roadmap in India because global buyers keep turning to Indian makers for affordable medicines, and complex products earn better margins. The main drivers are as follows. Complex launches. Difficult-to-make generics face fewer competitors. Backward integration. Own ingredient supply supports cost and reliability. Regulated markets. Sales in the United States and Europe diversify earnings. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Strides_Pharma_Science_performed_financially\"><\/span><strong>How has Strides Pharma Science performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Laurus_Labs_performed_financially\"><\/span><strong>How has Laurus Labs performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P\/E of 102.2, above the industry P\/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Natco_Pharma_performed_financially\"><\/span><strong>How has Natco Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_US_generics_and_complex_oncology_drug_stocks\"><\/span><strong>What risks should investors check before buying US generics and complex oncology drug stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying US generics and complex oncology drug stocks. Pricing in export markets. Competition can weigh on generic prices. Regulatory checks. Plant inspections can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_US_generics_and_complex_oncology_drug_stocks_investment_advice\"><\/span><strong>Is this list of US generics and complex oncology drug stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are US generics and complex oncology drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"US generics and complex oncology drug stocks are listed pharmaceutical companies that make generic formulations and active ingredients for regulated markets. Their earnings depend on approvals, launches and plant compliance. This list looks at three of them, Strides Pharma Science, Laurus Labs and Natco Pharma, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which US generics and complex oncology drug stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Strides Pharma Science, Laurus Labs and Natco Pharma. Based on the 22 October 2026 close, Strides Pharma Science traded at Rs 1,025.3, Laurus Labs at Rs 2,012.5 and Natco Pharma at Rs 785.15. Their return on equity ranges from 15.4% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 21.0%.\"}},{\"@type\":\"Question\",\"name\":\"Why do US generics and complex oncology drug stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"US generics and complex oncology drug stocks have a strong roadmap in India because global buyers keep turning to Indian makers for affordable medicines, and complex products earn better margins. The main drivers are as follows. Complex launches. Difficult-to-make generics face fewer competitors. Backward integration. Own ingredient supply supports cost and reliability. Regulated markets. Sales in the United States and Europe diversify earnings. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Strides Pharma Science performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.\"}},{\"@type\":\"Question\",\"name\":\"How has Laurus Labs performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P\/E of 102.2, above the industry P\/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.\"}},{\"@type\":\"Question\",\"name\":\"How has Natco Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying US generics and complex oncology drug stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying US generics and complex oncology drug stocks. Pricing in export markets. Competition can weigh on generic prices. Regulatory checks. Plant inspections can delay launches. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of US generics and complex oncology drug stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>US Generics and Complex Oncology Drug Stocks with a strong future roadmap: Strides Pharma Science, Laurus Labs and Natco Pharma. Compare price, valuation, return on equity and revenue growth as of 22 October 2026.<\/p>\n","protected":false},"author":35,"featured_media":325307,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,15324,8589,14124,15323,9049,15322],"class_list":["post-325308","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-finished-dosage-generic-maker-stocks","tag-laurus-labs","tag-natco-pharma","tag-regulated-market-pharma-shares","tag-strides-pharma-science","tag-us-generics-and-complex-oncology-drug-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["325307"],"rank_math_title":["US Generics and Complex Oncology Drug Stocks"],"rank_math_description":["Compare 3 US generics and complex oncology drug stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 22 Oct 2026."],"rank_math_focus_keyword":["US generics and complex oncology drug stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-finished-dosage-generics-anti-retroviral-and-active-ingredient-leader-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/325308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=325308"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/325308\/revisions"}],"predecessor-version":[{"id":325309,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/325308\/revisions\/325309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/325307"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=325308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=325308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=325308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}